YellowLegalPad Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YellowLegalPad

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	9/21/2010 3:42:20 AM
	Read Replies (1) of 1182

CHTP (6) September 20, 2010 4:44 PM EDT Needham & Company reiterates a 'Buy' rating on Chelsea Therapeutics (Nasdaq: CHTP), raises PT from $7 to $10. Needham analyst says, "Chelsea announced that Study 301, a Phase 3 trial of Droxidopa in Neurogenic Orthostatic Hypotension, met the primary endpoint of change from baseline on the composite Orthostatic Hypotension Questionnaire (OHQ). The outcome adds validation to the drug and the symptomatic assessments put in place by the company in this trial and the ongoing Study 306. We are favorably inclined into results from Study 306 in 2Q11, and continue to project a potential launch in 2012." To see all the upgrades/downgrades on shares of CHTP, visit our Analyst Ratings page. Shares gained $0.67 (+13.24%) today and closed at $5.73. streetinsider.com CRACKER

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next